These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 9672257)
1. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008 [TBL] [Abstract][Full Text] [Related]
4. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310 [TBL] [Abstract][Full Text] [Related]
5. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Tortora G; Caputo R; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Ciardiello F Clin Cancer Res; 1999 Apr; 5(4):875-81. PubMed ID: 10213224 [TBL] [Abstract][Full Text] [Related]
6. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433 [TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Bianco AR; Jiang Z; Agrawal S; Ciardiello F Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12586-91. PubMed ID: 9356493 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102 [TBL] [Abstract][Full Text] [Related]
9. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768 [TBL] [Abstract][Full Text] [Related]
12. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Ciardiello F; Tortora G Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874 [TBL] [Abstract][Full Text] [Related]
13. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Eller JL; Longo SL; Hicklin DJ; Canute GW Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411 [TBL] [Abstract][Full Text] [Related]
14. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; BarĂ³n AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
15. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Tortora G; Ciardiello F Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838 [TBL] [Abstract][Full Text] [Related]
16. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461 [TBL] [Abstract][Full Text] [Related]
17. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516 [TBL] [Abstract][Full Text] [Related]
18. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Huang SM; Harari PM Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065 [TBL] [Abstract][Full Text] [Related]
19. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447 [TBL] [Abstract][Full Text] [Related]
20. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Harari PM; Huang SM Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]